Premium
FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression
Author(s) -
Wider Christian,
Dachsel Justus C.,
Soto Alexandra I.,
Heckman Michael G.,
Diehl Nancy N.,
Yue Mei,
Lincoln Sarah,
Aasly Jan O.,
Haugarvoll Kristoffer,
Trojanowski John Q.,
Papapetropoulos Spiridon,
Mash Deborah,
Rajput Alex,
Rajput Ali H.,
Gibson J. Mark,
Lynch Timothy,
Dickson Dennis W.,
Uitti Ryan J.,
Wszolek Zbigniew K.,
Farrer Matthew J.,
Ross Owen A.
Publication year - 2009
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22442
Subject(s) - parkinson's disease , genotype , snp , biology , genetics , medicine , disease , single nucleotide polymorphism , gene
Genetic variation in fibroblast growth factor 20 ( FGF20 ) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and α‐synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient‐control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and α‐synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and α‐synuclein protein levels. © 2009 Movement Disorder Society